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Hospitalization for management of acute decompensated heart failure (HF) is associated with high rates of mor-
bidity, mortality, and rehospitalization independent of ejection 
fraction (EF).1,2 Epidemiological studies and data from clinical 
trials have shown that the early time period after a hospitaliza-
tion for HF is a particularly vulnerable interval.3–5 Although 
survival rates for all patients with HF have improved during 
the past several decades, the greatest gains have been made in 
the treatment of patients with HF with reduced EF (HFrEF).6
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A better understanding of the effect of hospitalization on 
the risk of future events is important for several reasons. First, 
it can help providers target care delivery to those patients at 
the highest risk of adverse outcomes. Second, it can be lever-
aged as part of a strategy to inform the design of future clinical 
trials in HF. Future trials, particularly in HF with preserved EF 
(HFpEF), are needed to further the advances that have been 
made in reducing HF morbidity and mortality. In addition to 
the development of new therapies, innovations in the design 
and implementation of randomized clinical trials, including 
targeted patient recruitment, will become progressively more 
important to increase the efficiency of these trials.
We hypothesized that the presence of a recent hospitaliza-
tion for HF can identify a high-risk patient population for 
enrollment in HF trials. We assessed the influence of time 
between previous HF hospitalization and randomization in 
the Candesartan in Heart failure: Reduction in Mortality and 
Original Article
© 2014 American Heart Association, Inc.
Circ Heart Fail is available at http://circheartfailure.ahajournals.org DOI: 10.1161/CIRCHEARTFAILURE.113.001281
Background—Hospitalization for acute heart failure (HF) is associated with high rates of subsequent mortality and 
readmission. We assessed the influence of the time interval between previous HF hospitalization and randomization in 
the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) trials on clinical outcomes in patients 
with both reduced and preserved ejection fraction.
Methods and Results—CHARM enrolled 7599 patients with New York Heart Association class II to IV HF, of whom 
5426 had a history of previous HF hospitalization. Cox proportional hazards regression models were used to assess the 
association between time from previous HF hospitalization and randomization and the primary outcome of cardiovascular 
death or unplanned admission to hospital for the management of worsening HF during a median of 36.6 months. For 
patients with HF and reduced or preserved ejection fraction, rates of cardiovascular mortality and HF hospitalization were 
higher among patients with previous HF hospitalization than those without. The risk for mortality and hospitalization 
varied inversely with the time interval between hospitalization and randomization. Rates were higher for patients with HF 
and reduced ejection fraction within each category. Event rates for those with HF with preserved ejection fraction and a 
HF hospitalization in the 6 months before randomization were comparable with the rate in patients with HF and reduced 
ejection fraction with no previous HF hospitalization.
Conclusions—Rates of cardiovascular death or HF hospitalization are greatest in those who have been previously hospitalized 
for HF. Independent of EF, rates of death and readmission decline as time from HF hospitalization to trial enrollment 
increased. Recent HF hospitalization identifies a high-risk population for future clinical trials in HF and reduced ejection 
fraction and HF with preserved ejection fraction.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00634400.   
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morbidity (CHARM) program on subsequent mortality and 
HF hospitalization in patients with HFrEF and HFpEF.
Methods
Patients
The CHARM program (ClinicalTrials.gov registration number 
NCT00634400) consisted of 3 trials, which enrolled 7599 patients 
with New York Heart Association class II to IV chronic HF and ran-
domized them to candesartan or placebo in addition to standard HF 
therapies. Patients were enrolled in the 3 trials based on left ventricu-
lar (LV) EF and treatment with an angiotensin-converting enzyme 
inhibitor. The CHARM trials were approved by an institutional re-
view committee at all sites, and all patients gave informed consent 
for participation in 1 of the 3 trials. CHARM-Added enrolled 2548 
patients with LVEF ≤40%, who were taking an angiotensin-convert-
ing enzyme inhibitor at baseline and had a cardiac hospitalization 
within 6 months. CHARM-Alternative consisted of 2028 patients 
with LVEF≤40%, who were intolerant to angiotensin-converting 
enzyme inhibitor. CHARM-Preserved enrolled 3023 patients with 
LVEF>40% (regardless of baseline angiotensin-converting enzyme 
inhibitor use or intolerance) and a previous cardiac hospitaliza-
tion. Patients were followed up for a median of 38 months overall, 
ranging from 34 months in CHARM-Alternative to 41 months in 
CHARM-Added.
Ascertainment of Time Since Hospitalization  
and Outcomes
The time between hospitalization and enrollment was investigator re-
ported. Investigators were asked whether the patient had a documented 
previous HF hospitalization and the month and year of the most recent 
previous hospitalization was recorded by the enrolling investigator on 
the case report form at the baseline visit. The total number of months 
between previous HF hospitalization and randomization were calcu-
lated and used for this analysis. If data were missing on the month 
of previous hospitalization (n=53), then it was imputed as January. 
If data were missing on the year of previous hospitalization, then the 
individual was excluded from this analysis (n=4). Two patients were 
excluded because of inconsistent dates. The primary outcome was the 
composite of cardiovascular death or HF hospitalization in each of the 
individual trials, and all-cause mortality in the overall CHARM pro-
gram. All first major cardiovascular end points, including HF hospital-
ization, myocardial infarction, stroke, and resuscitated sudden death, 
as well as all deaths, were reviewed and adjudicated by an independent 
clinical events committee. HF hospitalization was defined as the pres-
ence of typical symptoms and signs, treatment with an intravenous 
diuretic, and at least an overnight hospitalization. All deaths were clas-
sified as cardiovascular, which was further categorized as secondary to 
progressive HF, myocardial infarction, sudden death, or other, versus 
noncardiovascular. The detailed study design, entry criteria, and main 
results have all been previously described.7–11
Statistical Analysis
Baseline characteristics were stratified by substudy (Alternative and 
Added were compared with Preserved) and history of HF hospitaliza-
tion before enrollment. Categorical variables were compared using χ2 
tests, and continuous variables were compared using t tests. All tests 
were 2 sided, and a P value of <0.05 was considered statistically sig-
nificant. Event rates and 95% confidence intervals (CIs) comparing 
previous HF hospitalization were estimated. Rates were compared 
using the log-rank test stratified by substudy. Patients were grouped 
by EF (≤ or >40%), and the univariate association between EF and 
the primary outcome of all-cause mortality, as well as cardiovascu-
lar death or unplanned admission to hospital for the management of 
worsening HF, was analyzed in proportional hazards regression mod-
els and displayed on a Kaplan–Meier plot according to EF and previ-
ous HF hospitalization status. Covariate-adjusted hazard ratios (HRs) 
were calculated using the baseline predictors identified in previous 
analyses.12 The 5421 patients who had complete data on the timing 
of previous HF hospitalization were further stratified by elapsed time 
from previous HF hospitalization to randomization, and event rates 
were calculated for the primary outcomes. The trend in event rates 
across categories of months between HF hospitalization and ran-
domization was compared using Poisson regression. We explored the 
relationship between a HF hospitalization within the trial and sub-
sequent rehospitalization or death by fitting a Cox model in which 
participants were considered to be at risk for the event starting at the 
time of discharge for the first hospitalization. Stata/SE version 12.1 
(StataCorp, College Station, TX) was used for all analyses.
Results
Baseline Analyses
Of the 7599 patients enrolled in the CHARM program, Table 1 
lists the baseline characteristics of the 7593 CHARM patients 
with complete data (99.9%) included in this analysis broken 
down by EF above or below 40% and by history of previous hos-
pitalization for HF. A total of 5421 (71%) patients had a HF hos-
pitalization before enrollment in the CHARM program. Overall, 
those patients with a previous hospitalization were more likely 
to be women, with more advanced HF symptomatology, a lon-
ger duration of HF, and higher rates of hypertension, diabetes 
mellitus, and atrial fibrillation. Conversely, they were less likely 
to have had a previous myocardial infarction. There were no 
statistically significant differences between groups in rates of 
smoking, previous stroke, or assignment to candesartan.
Of those patients with a HF hospitalization before enroll-
ment, 3346 had HFrEF (LVEF≤40%) and 2075 had HFpEF 
(LVEF>40%). When compared with patients with HFrEF, 
patients with HFpEF and a previous hospitalization were 
slightly older, more likely to be women, and be in a lower New 
York Heart Association class. Patients with HFpEF were also 
more likely to be hypertensive with higher blood pressures 
and have hypertensive, rather than ischemic heart disease, as 
the cause of their HF.
HF Hospitalization, Ejection Fraction, and  
Event Rates
For patients with both HFrEF and HFpEF, event rates for the 
primary end point of time to cardiovascular death or hospital-
ization for HF were higher among those with a hospitalization 
for HF before randomization than those without a previous 
HF hospitalization (Figure 1). The magnitude of increased 
risk associated with a previous hospitalization was similar 
regardless of EF (EF≤40%: unadjusted HR, 1.74; P<0.001; 
adjusted HR, 1.56, 95% CI, 1.38–1.76; P<0.001 and EF>40%: 
unadjusted HR, 1.81; P<0.001; adjusted HR, 1.59; 95% CI, 
1.32–1.91; P<0.001), and there was no significant interaction 
between EF and previous hospitalization (P=0.76).
Among patients with HFpEF, annualized event rates of car-
diovascular death or HF hospitalization for those with a HF 
hospitalization before randomization were comparable with the 
rate in patients with HFrEF and no previous HF hospitalization 
(10.1; 95% CI, 9.3–11.0 versus 10.1; 95% CI, 9.1–11.2 per 100 
patient years; Table 2). Overall, patients with HFpEF had lower 
rates of all-cause mortality (unadjusted HR, 0.52; P<0.001 and 
adjusted HR, 0.86; 95% CI, 0.72–1.03; P=0.10) and the com-
posite end point of cardiovascular death/HF hospitalization 
(unadjusted HR, 0.55; P<0.001 and adjusted HR, 0.94; 95% 
CI, 0.80–1.09; P=0.39) compared with patients with HFrEF 
 by guest on July 12, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
592  Circ Heart Fail  July 2014
although the difference did not persist after adjustment for sig-
nificant covariates. Event rates for patients with HFpEF were 
similar if HFpEF was defined as an EF≥50% (Table 3). When 
the time period between previous hospitalization and enrollment 
in CHARM was further broken down, patients with the short-
est interval between hospitalization and randomization were at 
the greatest risk of death or hospitalization for HF during the 
trial (Figure 2). Event rates were higher for patients with HFrEF 
within each time period, and the trend in event rates was statisti-
cally significant for patients with both HFpEF and HFrEF.
Within all 4 subgroups, annualized event rates for a sec-
ond HF hospitalization or death after a hospitalization for HF 
within CHARM were markedly elevated when compared with 
the rates of a first HF hospitalization or death (Table 2). After 
a HF hospitalization within CHARM, those patients who were 
hospitalized for HF before enrollment continued to display an 
elevated risk for a second event (HF hospitalization or death) 
during the trial when compared with those who were not hos-
pitalized before enrollment (Figure 3). Although patients with 
HFpEF continued to have lower rates of a second hospitaliza-
tion for HF or death than those with HFrEF overall (HR, 0.79; 
95% CI, 0.68–0.90), patients with HFpEF and a previous hos-
pitalization for HF had higher second event rates after an in-
trial hospitalization for HF than those with a HFrEF who only 
Table 1. Baseline Characteristics
Overall (n=7593) HFrEF (n=4572) HFpEF (n=3021)
No Previous HF 
Hospitalization
Previous HF 
Hospitalization P Value
No Previous HF 
Hospitalization
Previous HF 
Hospitalization P Value
No Previous HF 
Hospitalization
Previous HF 
Hospitalization P Value
n 2172 5421 ... 1226 3346 ... 946 2075 ...
Age, y 66 (11) 65 (11) 0.88 65 (10) 65 (11) 0.53 66 (11) 67 (11) 0.29
Women 634 (29) 1764 (33) 0.004 289 (24) 898 (27) 0.03 345 (37) 866 (42) 0.001
Current smoker 322 (15) 792 (15) 0.81 179 (15) 526 (16) 0.35 143 (15) 266 (13) 0.09
BMI, kg/m2 28.4 (5.1) 28.2 (5.6) 0.07 27.9 (4.7) 27.6 (5.3) 0.09 29.2 (5.6) 29.2 (5.9) 0.98
Candesartan 1078(50) 2721 (50) 0.66 602 (49) 1684 (50) 0.46 476 (50) 1037 (50) 0.86
NYHA class <0.001 0.01 <0.001
  II 1077 (50) 2338 (43) 460 (38) 1120 (33) 617 (65) 1218 (59)
  III–IV 1095 (50) 3083 (57) 766 (62) 2226 (67) 329 (35) 857 (41)
Time since HF dx, y 3.1 (3.8) 3.9 (4.6) <0.001 3.4 (3.9) 4.1 (4.5) <0.001 2.7 (3.6) 3.5 (4.6) <0.001
Hypertension 1125 (52) 3056 (56) <0.001 550 (45) 1689 (51) 0.001 575 (61) 1367 (66) 0.01
Previous MI 1315 (61) 2684 (50) <0.001 785 (64) 1878 (56) <0.001 530 (56) 808 (39) <0.001
Diabetes mellitus 483 (22) 1677 (31) <0.001 267 (22) 1037 (31) <0.001 216 (23) 640 (31) <0.001
Previous stroke 185(9) 478 (9) 0.68 100 (8) 295 (9) 0.48 85 (9) 183 (9) 0.88
Atrial fibrillation 434 (20) 1649 (30) <0.001 238 (19) 964 (29) <0.001 196 (21) 685 (33) <0.001
Cause of HF
  Ischemic 1519 (70) 3157 (58) <0.001 853 (70) 2119 (63) <0.001 666 (70) 1038 (50) <0.001
  Idiopathic 290 (13) 1036 (19) <0.001 246 (20) 817 (24) 0.002 44 (5) 219 (11) <0.001
  Hypertensive 235 (11) 746 (14) 0.001 69 (6) 228 (7) 0.15 166 (18) 518 (25) <0.001
  HR, bpm 71 (13) 74 (13) <0.001 72 (13) 74 (13) <0.001 69 (12) 72 (12) <0.001
  SBP, mm Hg 131 (19) 131 (19) 0.22 128 (18) 127 (19) 0.048 135 (18) 137 (19) 0.05
  DBP, mm Hg 77 (10) 77 (11) 0.12 76 (10) 76 (11) 0.14 78 (10) 78 (11) 0.97
All values presented as n (%) or mean (SD). BMI indicates body mass index; DBP, diastolic blood pressure; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
HF with preserved EF; HR, heart rate; MI, myocardial infarction; NYHA, New York Heart Association; and SBP, systolic blood pressure. 
HFrEF,
HFrEF,
Figure 1. Previous hospitalization for heart failure 
(HF) is associated with increased risk of cardiovas-
cular (CV) death and HF hospitalization independent 
of ejection fraction (EF). CI indicates confidence 
interval; and HR, hazard ratio.
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experienced a HF hospitalization during the trial (HR, 0.76; 
95% CI, 0.59–0.97; P=0.027).
Discussion
The CHARM program enrolled patients with symptomatic HF 
across a broad spectrum of EF s. The majority of patients in 
CHARM (71%) experienced a hospitalization for HF before 
enrollment, and the current analysis demonstrates that this his-
tory of an acute HF event is a powerful predictor of adverse 
cardiovascular outcomes for patients with both HFrEF and 
HFpEF during the trial. Moreover, the time between the last 
HF hospitalization and enrollment was itself a powerful pre-
dictor of subsequent event rates. These findings have implica-
tions for the design of future clinical trials.
Previously published findings from acute and chronic HF 
populations have reported varied estimates of subsequent mor-
tality and rehospitalization rates for patients with HFpEF and 
HFrE.13–25 Some studies have shown that patients with HF face 
a similar magnitude of risk regardless of EF,13–15,19,25 whereas 
others have demonstrated lower event rates in patients with 
HFpEF when compared with HFrEF.16–18,22–24 This disparate 
finding about the effect of EF on event rates is also seen when 
the studies are grouped into acute HF,13–17 versus chronic, 
prevalent HF.18–25 The admixture of different combinations of 
patients into single studies is likely responsible for some of 
the published disparities in risk.
The current analysis that stratified CHARM patients by EF 
and the presence or absence of a recent hospitalization for HF 
before enrollment provides clarification of the previous dis-
crepant findings. Overall, and for patients with both HFpEF 
and HFrEF, we observed an inverse relationship between time 
from HF hospitalization and randomization into the trial and 
event rates within the trials. In addition, although the magni-
tude of increased hazard seen with a previous HF hospitaliza-
tion was similar regardless of EF, patients with low EF had 
consistently higher event rates than those with HFpEF.
Event rates in cardiovascular clinical trials continue to decline 
over time because new interventions that have been tested and 
proven efficacious in previous trials are applied to clinical care.26 
As a result, increasing numbers of patients are needed to show 
a difference between treatment groups because the net number 
of clinical events, rather than the number of patients enrolled in 
a trial, ultimately determines a trial’s overall power to detect a 
significant difference.26,27 Historically, the development of the 
composite end point was one of the first ways trial design was 
adapted to leverage this knowledge.28 Further innovations in the 
design and implementation of clinical trials, including targeted 
patient recruitment, can increase the efficiency of HF trials. 
The present data demonstrate that event rates for patients with 
HFpEF and a recent HF hospitalization approximate those of 
patients with HFrEF and no hospitalization before enrollment. 
This relationship persisted when HFpEF is defined more rig-
orously as clinical HF with an EF≥50%. A history of recent 
hospitalization for HF, therefore, provides a means to identify a 
high-risk patient population. Although mitigating risk in a high-
risk population may not be the goal of every trial, we think that 
this strategy can inform enrollment strategies for some future 
clinical trials. It is important to design trials with a recruitment 
strategy that most effectively identifies the target population (eg, 
if a therapy is designed to work in lower risk patients, a recent 
hospitalization for HF is unlikely to identify those individuals).
The current analysis also reinforces the concept that a HF hos-
pitalization is a sentinel event that can be used to identify patients 
who are at an increased risk for additional events. Patients who 
were hospitalized for HF before the trial were more likely to 
have recurrent hospitalizations or die during the trial, regardless 
of EF. During the course of a HF trial, such as CHARM, many 
patients experience multiple events that are positively adjudicated 
by the clinical events committee. A previous analysis of CHARM 
Table 3. Event Rates in Patients With HFpEF and EF≥50%
HFpEF (EF≥50%; n=1949)
No Previous  
HF Hospitalization 
(n=642)
Previous  
HF Hospitalization 
(n=1307)
CV death/HF hospitalization 5.4 (4.4–6.6) 10.8 (9.7–11.9)
CV death 2.7 (2.0–3.5) 4.3 (3.7–5.0)
All-cause mortality 4.2 (3.4–5.2) 6.5 (5.7–7.3)
All death or HF hospitalization 6.7 (5.6–8.0) 12.3 (11.2–13.6)
HF hospitalization 3.1 (2.4–4.0) 8.5 (7.6–9.5)
HF death 0.6 (0.3–1.0) 1.4 (1.1–1.8)
Second HF hospitalization or death 
after a HF hospitalization (n=311)
21.1 (12.3–36.4) 61.4 (52.7–71.6)
Rates are per 100 patient years. CV indicates cardiovascular; and HFpEF, 
heart failure with preserved ejection fraction.
Table 2. Event Rates Stratified by Substudy and Previous HF Hospitalization
Complete Study Data*
HFrEF (n=4572) HFpEF (n=3021)
No Previous HF Hospitalization Previous HF Hospitalization No Previous HF Hospitalization Previous HF Hospitalization
CV death/HF hospitalization 10.1 (9.1–11.2) 17.9 (17.0–18.8) 5.5 (4.7–6.5) 10.1 (9.3–11.0)
CV death 6.4 (5.6–7.2) 9.7 (9.1–10.3) 2.9 (2.3–3.6) 4.3 (3.8–4.8)
All-cause mortality 7.6 (6.7–8.6) 11.7 (11.0–12.4) 4.0 (3.4–4.9) 6.1 (5.5–6.8)
All death or HF hospitalization 11.3 (10.2–12.5) 19.5 (18.5–20.5) 6.5 (5.6–7.5) 11.5 (10.6–12.4)
HF hospitalization 5.4 (4.7–6.2) 12.3 (11.5–13.0) 3.2 (2.6–4.0) 7.9 (7.2–8.7)
HF death 1.2 (0.9–1.7) 3.5 (3.1–3.9) 0.6 (0.4–1.0) 1.4 (1.1–1.7)
Second HF hospitalization or death  
after a HF hospitalization (n=1525)
45.0 (36.5–55.5) 78.7 (72.7–85.1) 29.1 (19.7–43.1) 60.9 (53.8–69.0)
Rates are per 100 patient years. CV indicates cardiovascular; HFpEF, heart failure with preserved ejection fraction; and HFrEF, HF with preserved EF.
*P value <0.05 for all event rate comparisons between no previous and previous HF hospitalization within HFrEF and HFpEF categories.
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demonstrated that the risk of death is directly related to the dura-
tion and frequency of HF hospitalization.1 The current analysis 
demonstrates that this principle holds true in patients with HFrEF 
and HFpEF and extends the period of elevated risk to include hos-
pitalizations that occurred before the trial start date. Because this 
analysis includes only patients who survived their previous hospi-
talization and lived to be randomized in the CHARM program, the 
increased risk associated with a previous hospitalization is likely 
underestimated because the sickest patients likely died during or 
shortly after hospitalization before they could be randomized. 
In general, current methods of survival analysis are based on a 
time to first event model and do not take into account these other 
events, which are important to both patients and providers. Future 
strategies in trial design, such as time to multiple events, may also 
be a novel way to use more of the data collected during a trial and 
provide composite end points that are easy to interpret.29,30
Some limitations of this analysis should be noted. The HF 
hospitalizations before randomization in CHARM were not for-
mally adjudicated events. It is possible that some of those events 
would not meet the standards of a clinical end points committee; 
however, nondifferential misclassification of HF hospitalization 
would dilute our findings and have biased the results toward the 
null. However, event rates at 24 months in CHARM patients who 
fit enrollment criteria for Efficacy of Vasopressin antagonism in 
hEart failuRE: outcome Study with Tolvaptan (EVEREST),31 
a trial of acute HF, are similar; all-cause mortality (EVEREST 
26% versus CHARM 28%) and cardiovascular death or HF hos-
pitalization (EVEREST 41% versus CHARM 41%). The EFs 
in CHARM were site reported using several techniques and not 
verified by a core laboratory. Any noise created by the different 
techniques or imprecise measurement should be diminished in 
light of the large number of events. Finally, as with other clini-
cal trials, these findings may not be generalizable to the general 
population of patients with HF.
In summary, rates of cardiovascular death or HF hospital-
ization are greatest in those with a previous HF hospitalization 
and decline with time between hospitalization and randomiza-
tion across a broad spectrum of EF. The use of a history of 
recent HF hospitalization as an inclusion criterion for future 
clinical trials can increase trial efficiency. Acute exacerba-
tions of HF requiring hospitalization signify a vulnerable time 
period in a patient’s life and should trigger intensified man-
agement and heightened surveillance for additional events.
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Figure 2. A, Increasing rates of cardiovascular (CV) death and heart failure (HF) hospitalization with more recent hospitalization before 
enrollment. B, Mortality rates increase as time between previous hospitalization and enrollment decreases. EF indicates ejection fraction.
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Figure 3. Time to death or second heart failure (HF) hospitalization 
after an in-trial HF hospitalization in Candesartan in Heart failure: 
Reduction in Mortality and morbidity (CHARM) in patients stratified 
by ejection fraction (EF) and presence or absence of a HF hospi-
talization before enrollment. HFpEF indicates heart failure with pre-
served ejection fraction; and HFrEF, HF with preserved EF.
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CLINICAL PERSPECTIVE
Patients who were hospitalized for a heart failure (HF) exacerbation before enrollment in the Candesartan in Heart failure: 
Reduction in Mortality and morbidity (CHARM) program experienced higher event rates than those without a baseline his-
tory of HF hospitalization. Independent of ejection fraction, patients with a recent HF hospitalization were at the highest risk 
of death and readmission, with a steady decline in the rates observed as time between HF hospitalization and randomization 
increased. The identification of baseline patient characteristics associated with risk for future events, such as a history of a 
recent HF hospitalization, can be used to inform enrollment criteria for future HF trials. Targeted enrollment of individuals 
with a high risk for events can increase the efficiency of future HF trials.
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